SLSBio(Specialty Lab Solution Bio) Co., Ltd
Founded 2007, KOSDAQ-listed 2023, SLSBio provides pharmaceutical quality control, drug development support, and in vitro diagnostics.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureSLSBio was established in January 2007 and listed on KOSDAQ in October 2023, operating in pharmaceutical quality control, new drug development support, and in vitro diagnostic devices. The company provides pharmaceutical quality control services including finished drug product quality testing and comparative dissolution testing, and is developing diagnostic kits using its proprietary NTMD technology. Designated by the Ministry of Food and Drug Safety as a contract testing institution, SLSBio operates 320 analytical instruments including LC/MS and UPLC covering approximately 300 test items, with a research organization of 9 staff comprising 2 PhDs, 2 master's degree holders, and 5 bachelor's degree holders.
Products & technology
- Finished pharmaceutical product quality testingTesting to verify pharmaceutical quality according to standards and test methods approved by the Ministry of Food and Drug Safety
- Comparative dissolution testingIn-vitro dissolution comparison test between two formulations with the same active ingredient and administration route to demonstrate pharmaceutical equivalence
Regulatory approvals
data.go.kr5 Korean MFDS device approvals · 2013–2021
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2021-07-14Product approval · Class 3체외 제허 21-603 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2021-01-21Product approval · Class 3체외 제허 21-56 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2020-05-21Product approval · Class 3체외 제허 20-381 호
- MFDSIVD reagents for allergy testRevoked2018-08-28Product approval · Class 2체외 제인 18-4682 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2013-09-25Product approval · Class 3체외 제허 13-1639 호
R&D and key agreements
Source: DART corporate disclosureNTMD 기술 기반 진단키트 · 체외진단 · 개발 중 · Developing a diagnostic kit using proprietary NTMD technology; human and animal test kits have already been developed
Companies approved for the same productsBiotech & Drug Discovery
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
KOSDAQ-listed point-of-care immunodiagnostics company supplying diagnostic cartridges and the ichroma/AFIAS instrument series.
GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.
KOSDAQ-listed in-vitro diagnostics company selling PROTIA Allergy-Q allergy diagnostic products domestically and in 80+ countries.
KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.
Founded in 2011 and KOSDAQ-listed in 2019, Sugentech develops multiplex immunoblot, point-of-care, and digital healthcare diagnostics.
KOSDAQ-listed vaccine maker supplying oral cholera vaccine to UNICEF alongside a biologics CRMO business.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
KOSDAQ-listed IVD company producing COVID-19 and HIV point-of-care diagnostic reagents alongside rubber products and entertainment businesses.
Founded in 1999 and listed on KONEX in 2017, Median Diagnostics develops and manufactures immunoassay, molecular, and point-of-care in vitro diagnostic kits for animal diseases.
Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.
KOSDAQ-listed IVD company using SG Cap™ multiplex diagnostic technology for infectious disease, cancer, and companion animal testing.
KOSDAQ-listed in-vitro diagnostics company developing the LabChip-based VERI-Q molecular diagnostic device series.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition